News
CSMG Technologies Live Tissue Connect Subsidiary's Surgical Sealing System Product Performance to Be Presented at International Congress
Corpus Christi, TX, May 21, 2008 -- CSMG Technologies, Inc., (OTCBB: CTGI - News), a technology management company, and its subsidiary Live Tissue Connect ("LTC") announced that the performance of LTC's newly developed bipolar vessel sealing system will be presented at an international congress by Robert D. Tucker PhD, MD. Dr. Tucker is with the University of Iowa, Department of Pathology and the Department of Biomedical Engineering. He will be presenting his teams' comparative results with the LTC bipolar sealing system at the 17th annual Congress of the International Society for Gynecologic Endoscopy, the World Congress of Gynecologic Endoscopy and SEGI Annual meeting which will be held in Bari, Italy from June 4th to 7th 2008.
Don Robbins, CEO of CSMG Technologies and LTC, said, "It is an honor to have the results of LTC's bipolar artery, vein and duct sealing system accepted for presentation at such a well known and respected congress. This 17th annual meet focuses on advances in new medical technology for gynecology, one of the many areas where LTC's bipolar sealing system has broad application. We are a globally focused company and will continue to use international congresses and meetings to present our results and explore distribution options.”
Frank D'Amelio, President of LTC stated, "Dr. Tucker will be presenting a comparative study that focuses on the key parameters of vessel sealing pressure, tissue sticking and thermal spread. This meeting in Bari, Italy is recognized as one of the leading international meetings to present evidence-based, technological advances in the field of women’s health. It is important for our company to be performing comparative clinical studies, have those results reviewed and accepted for presentation and then reporting such to the world wide medical community.”
About Live Tissue Connect
LTC's surgical tissue bonding/welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC holds approximately 31 patents and pending patents in the U.S., Australia, Canada, European Union, Ukraine, and other countries.
For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.
Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to: www.csmgtechinternational.com/contact_information.html and fill-in information.
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.